Bausch Health Companies | VRX - Debt



Bausch Health Companies reported $21.74B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Amgen USD 56.2B 1.18B Jun/2025
ANI Pharmaceuticals USD 621.56M 1.26M Jun/2025
Aurora Cannabis CAD 101.63M 648K Jun/2025
Bausch Health Companies USD 21.74B 228M Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Canopy Growth CAD 327.8M 161.87M Jun/2025
Corcept Therapeutics USD 6.6M 6.6M Jun/2025
Danaher USD 17.36B 878M Jun/2025
Drreddys Laboratories INR 48.64B 2.44B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Novo Nordisk 118.72B 61.75B Mar/2025
Pacira USD 580.49M 2.88M Jun/2025
Perrigo USD 3.65B 24.4M Jun/2025
Prestige Brands USD 1.04B 27.25M Jun/2025
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Zoetis USD 6.79B 214M Jun/2025